Antipodes Partners LTD Immunome Inc. Transaction History
Antipodes Partners LTD
- $3.16 Billion
- Q1 2025
A detailed history of Antipodes Partners LTD transactions in Immunome Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 14,164 shares of IMNM stock, worth $120,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,164Holding current value
$120,252% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IMNM
# of Institutions
149Shares Held
66.4MCall Options Held
47.3KPut Options Held
4.31M-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.55MShares$64.1 Million0.03% of portfolio
-
Redmile Group, LLC San Francisco, CA5.36MShares$45.5 Million3.79% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.36MShares$37 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.31MShares$36.6 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.08MShares$34.6 Million2.16% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $103M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...